In: Dementia and geriatric cognitive disorders, 33 (2012), Nr. 5. pp. 341-353. ISSN 1420-8008
Preview |
PDF, English
Download (283kB) | Terms of use |
Abstract
Aim: Determine whether patients with Alzheimer’s disease demonstrating functional and cognitive decline, following 24-48 weeks of open-label treatment with 9.5 mg/24 h (10 cm(2)) rivastigmine patch, benefit from a dose increase in a double-blind (DB) comparative trial of two patch doses. Methods: Patients meeting prespecified decline criteria were randomized to receive 9.5 or 13.3 mg/24 h (15 cm(2)) patch during a 48-week, DB phase. Coprimary outcomes were change from baseline to week 48 on the Instrumental Activities of Daily Living domain of the Alzheimer’s Disease Cooperative Study-Activities of Daily Living (ADCS-IADL) scale and the Alzheimer’s Disease Assessment Scale-cognitive subscale (ADAS-cog). Safety and tolerability were assessed. Results: Of 1,584 patients enrolled, 567 met decline criteria and were randomized. At all timepoints, ADCS-IADL and ADAS-cog scores favoured the 13.3 mg/24 h patch. The 13.3 mg/24 h patch was statistically superior to the 9.5 mg/24 h patch on the ADCS-IADL scale from week 16 (p = 0.025) onwards including week 48 (p = 0.002), and ADAScog at week 24 (p = 0.027), but not at week 48 (p = 0.227). No unexpected safety concerns were observed. Conclusions: The 13.3 mg/24 h rivastigmine patch significantly reduced deterioration in IADL, compared with the 9.5 mg/24 h patch, and was well tolerated. Copyright © 2012 S. Karger AG, Basel
Document type: | Article |
---|---|
Journal or Publication Title: | Dementia and geriatric cognitive disorders |
Volume: | 33 |
Number: | 5 |
Publisher: | S. Karger AG |
Date Deposited: | 22 Dec 2014 08:09 |
Date: | 2012 |
ISSN: | 1420-8008 |
Page Range: | pp. 341-353 |
Faculties / Institutes: | Service facilities > Zentralinstitut für Seelische Gesundheit |
DDC-classification: | 610 Medical sciences Medicine |
Controlled Keywords: | Alzheimer-Krankheit, Rivastigmin |